Therapy of multiple myeloma: Indications and options;Therapie des multiplen myeloms: Indikationen und möglichkeiten

Internist

Volumn 48, Issue 12, 2007, Pages 1343-1348

  Peest, D ^a   Ganser, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bisphosphonate; High dose chemotherapy; Multiple myeloma; Stem cell transplantation; Thalidomide

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; COMORBIDITY; HUMAN; LONG TERM CARE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; QUALITY OF LIFE; REMISSION; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISONE; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TUMOR BURDEN;

EID: 37749040579     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1959-x     Document Type: Review

References (26)

1. Alexander DD, Mink PJ, Adami HO et al. (2007) Multiple myeloma: a review of the epidemiologic literature Int J Cancer (Supp 12) 120: 40-61
2. Alexanian R, Haut A, Khan AU et al. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680-1685
3. Alyea E, Weller E, Schlossman R et al. (2003) Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 32: 1145-1151
4. Attal M, Harrousseau JL, Facon T et al. (1996) Intergroupe francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 335: 1844-1845
5. Barlogie B, Desikan R, Eddlemon P et al. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492-494
6. Berenson JR, Lichtenstein A, Porter L et al. (1996) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. N Engl J Med 334: 488-493
7. Blade J, Samson D, Reece D et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102: 1115-1123
8. Bruno B, Rotta M, Patriarca F et al. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110-1120
9. Child JA, Morgan GJ, Davies FE et al. (2003) High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883
10. Dimopoulos MA, Zervas K, Kouvatseas G et al. (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12: 991-995
11. Durie BG, Kyle RA, Belch A et al. (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4: 379-398
12. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842-854
13. Greipp PR, San Miguel J, Durie BG et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420
14. Hari P, Pasquini MC, Vesole DH (2006) Cure of multiple myeloma - more hype, less reality. Bone Marrow Transplant 37: 1-18
15. Koreth J, Cutler CS, Djulbegovic B et al. (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13: 183-196
16. Kröger N, Sayer HG, Schwerdtfeger R et al. (2002) Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100: 3919-3924
17. Lahtinen R, Laakso M, Palva I et al. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340: 1049-1052
18. McCloskey EV, MacLennan IC, Drayson MT et al. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100: 317-325
19. McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2: 822-824
20. Myeloma Trialists' Cooperative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16: 3832-3842
21. Palumbo A, Bringhen S, Petrucci MT et al. (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104: 3052-3057
22. Richardson PG, Barlogie B, Berenson J et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617
23. Richardson PG, Schlossman RL, Weller E et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067
24. Richardson PG, Sonneveld P, Schuster MW et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498
25. Rosen LS, Gordon D, Kaminski M et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387
26. Tricot G, Vesole DH, Jagannath S et al. (1996) Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198